BioClad is revolutionising hygienic spaces in hospitals and healthcare centres, the leisure sector and the restaurant industry worldwide using antimicrobial technology.
BioClad products comprise wall cladding, wall and door protection, floors and an innovative new wash station unit. Antimicrobial silver-ion technology is impregnated into products during manufacturing, which kills 99.9% of microbes and protects against E.Coli, MRSA and Influenza. BioClad’s recent commission is the biggest contract in the sector, for Hinkley Point C Nuclear Power Station.
BioClad, which was launched in 2008 and employs 20 people, has marked a 2000 per cent growth in exporting since broadening its horizons into international trade in 2011.
Global sales account for 25 per cent of BioClad’s £10 million current turnover – an increase of £1.5 million on last year. BioClad is blazing an export trail in Australia, Canada, India, Saudi Arabia, UAE and Mexico. BioClad has recently opened an Australian subsidiary in Perth and is poised to enter European markets. With the global flooring market predicted to be worth $300 billion by 2020 the world is BioClad’s oyster.